Effective, high-quality cell line development (CLD) is essential for success in the commercialization of protein biologics, but there is no one right way to tackle it. Some companies have extensive in-house capabilities and look for reliable equipment suppliers to help streamline early-stage development and enable a smooth transition to manufacturing. On the other end of the spectrum, certain companies need a fully outsourced solution to provide cell lines, products, and experienced professionals to oversee the entire CLD project. And others need a hybrid approach for a custom CLD solution that best meets their needs. A synergistic, single-vendor approach increases collaboration and reduces project management requirements and overall costs.
This white paper highlights the key hurdles and points to consider when establishing a CLD process and how early decision-making can significantly impact later stages. Explore the advantages and disadvantages of various approaches to CLD and learn about Sartoriusâ€™ whole CLD portfolio, which encompasses instruments, CLD services, technology licenses, cell culture media, and related services.
Click here to download this white paper.